Should you buy Anika Therapeutics stock? (NasdaqGS:ANIK). Let's see how it does in our automated value investing analysis system.
Based on historical returns, we believe that Anika Therapeutics can grow its free cash at a rate of about 2%. That's positive!
(Anika Therapeutics stock price per share)
||ANIK Fair Price
(based on intrinsic value)
||ANIK Safety Price (based on a variable margin of safety)||$21.22|
||PE Ratio versus Sector||18% lower than other Healthcare stocks|
|PE Ratio versus Industry||71% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||73%|
We believe that Anika Therapeutics may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Anika Therapeutics looks like a price in the fair value range. Based on our analysis—if the company keeps making money the way it has been—you could be looking at a good stock. See Before You Buy for your next steps.
Does Anika Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles